Quarterly report pursuant to Section 13 or 15(d)

Merger with Private Molecular - Summary of Allocation of Purchase Consideration to Assets Acquired and Liabilities Assumed (Detail)

v3.8.0.1
Merger with Private Molecular - Summary of Allocation of Purchase Consideration to Assets Acquired and Liabilities Assumed (Detail) - Threshold
$ in Thousands
Aug. 01, 2017
USD ($)
Business Acquisition [Line Items]  
Cash and cash equivalents $ 11,216
Prepaid expenses and other current assets 945
In-process research and development (IPR&D) 26,623
Accounts payable, accrued expenses (2,009)
Warrant liability (1,121)
Net assets acquired $ 35,654